Fast disease
Researchers at the Georgia Institute of Technology and the Centres for Disease Control and Prevention have developed a faster method for detecting infections caused by Staphylococcus aureus.
Researchers at the Georgia Institute of Technology and the Centres for Disease Control and Prevention have developed a faster method for detecting infections caused by Staphylococcus aureus.1 They have produced a multiple reaction monitoring liquid chromatography method with tandem mass spectrometric detection via phage amplification detection. The phage amplification detection detects an amplified capsid protein from a specific phage.
To perform their test, the team first injected a known amount of metabolically labelled 15N reference bacteriophage into the S. aureus sample. After a 2 h incubation the sample was subjected to a 3 min trypsin digest and then analysed by high-throughput liquid chromatography with tandem mass spectrometric detection. Quantitation was made possible by comparing peak areas of target peptides from the metabolically labelled 15N bacteriophage peptide internal standard with that of the wild-type 14N peptides that were produced by phage amplification and subsequent digestion when the host bacteria was present. A labelled species differs from an unlabelled one in terms of mass but exhibits almost identical chemical properties.
A 6-point calibration curve was established and standards ranged from 5.0 × 104 colony forming units (CFU) mL−1 to 2.0 × 106 CFU mL−1. The 15N peaked at 1.0 × 109 plaque forming units mL−1.
The study concluded that amplification with 15N joined withLC–MS–MS provides a quick, sensitive and accurate method for detecting S. aureus.
1 John R. Barr et al., Molecular & Cellular Proteomics, 11, M111.012849 (2012).
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
